Ignite Creation Date:
2024-05-06 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 2:17 PM
Study NCT ID:
NCT05104866
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-23
First Post:
2021-10-04
Brief Title:
A Phase-3 Open-Label Randomized Study of Dato-DXd Versus Investigators Choice of Chemotherapy ICC in Participants With Inoperable or Metastatic HR-Positive HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy TROPION-Breast01
Sponsor:
Organization:
AstraZeneca